-
1Academic Journal
Authors: B. Y. Alekseev, K. M. Nyushko, S. A. Reva, A. K. Nosov, D. G. Prokhorov, T. T. Andabekov, А. А. Krasheninnikov, E. Y. Safronova, А. S. Kalpinskiy, M. А. Gusniev, A. D. Kaprin, Б. Я. Алексеев, К. М. Нюшко, С. А. Рева, А. К. Носов, Д. Г. Прохоров, Т. Т. Андабеков, А. А. Крашенинников, Е. Ю. Сафронова, А. С. Калпинский, М. А. Гусниев, А. Д. Каприн
Source: Research and Practical Medicine Journal; Том 3, № 4 (2016); 8-18 ; Research'n Practical Medicine Journal; Том 3, № 4 (2016); 8-18 ; 2410-1893 ; 10.17709/2409-2231-2016-3-4
Subject Terms: многоцентровое исследование, oligometastasis, nodal progression, the saving salvaging lymph node dissection, immediate and long-term results of treatment, multi-center study, олигометастазы, лимфогенное прогрессирование, спасительная сальважная лимфаденэктомия, непосредственные и отдаленные результаты лечения
File Description: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/158/156; Злокачественные новообразования в России в 2014 г. (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2016. Доступно по: http://www.oncology.ru/service/statistics/malignant_tumors/2014. pdf. Дата обращения 17.09.2016 г.; Han M., Partin A. W., Pound C. R., Epstein J. I., Walsh P. C. Long-term biochem- ical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the15-year Johns Hopkins experience. UrolClin North Am. 2001; 28: 555–565.; Simmons M. N., Stephenson A. J., Klein E. A. Natural history of biochemical recur- rence after radical prostatectomy: risk assessment for secondary therapy. EurUrol. 2007; 51: 1175–1184. DOI: http://dx.doi.org/10.1016/j.eururo.2007.01.015; Suardi N., Porter C. R., Reuther A. M., Walz J., Kodama K., Gibbons R. P., et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer. 2008; 112: 1254–1263. DOI: http://dx.doi.org/10.1002/cncr.23293; Roehl K. A., Han M., Ramos C. G., Antenor J. A., Catalona W. J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004; 172: 910–914. DOI: http://dx.doi.org/10.1097/01.ju.0000134888.22332.bb; Pound C. R., Partin A. W., Eisenberger M. A., Chan D. W., Pearson J. D., Walsh P. C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999 May; 281 (17): 1591–1597. DOI: http://dx.doi.org/10.1001/jama.281.17.1591; Schweizer M. T., Zhou X. C., Wang H., Yang T., Shaukat F., Partin A. W., et al. Me- tastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol. 2013; 24 (11): 2881–2886. DOI: http://dx.doi.org/10.1093/annonc/mdt335; Garcia J. R., Morenco C., Valls F., Cozar P., Bassa P., Soler M., et al. Diagnostic performance of bone scintigraphy and 11C–Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. Rev Esp Med Nucl Imagen Mol. 2015 May-Jun; 34 (3): 155–161. DOI: http://dx.doi.org/10.1016/j.remn.2014.08.001; Von Eyben F. E., Kairemo K. Metaanalysis of 11C-holine and 18F-choline PET/CT Research’n Practical Medicine Journal. 2016, V. 3, №4, с. 8-18 for management of patients with prostate cancer. Nucl Med Commun. 2014; 35 (3): 221–230. DOI: http://dx.doi.org/10.1097/mnm.0000000000000040; Afshar-Oromieh A., Zechmann C. M., Malcher A., Eder M., Eisenhut M., Lin- hart H. G., et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Jan; 41 (1): 11–20. 10.1007/s00259–013–2525–5. DOI: http://dx.doi.org/10.1007/s00259–013–2525–5; Власова О. П., Герман К. Э., Крылов В. В., Петриев В. М., Эпштейн Н. Б. Новые радиофармпрепараты для диагностики и лечения метастатического рака предстательной железы на основе ингибиторов простатспецифического мембранного антигена. Вестник Российской академии медицинских наук. 2015; 70 (3): 360–366. DOI: http://dx.doi.org/10.15690/vramn.v70i3.1334; Eiber M., Maurer T., Souvatzoglou M., Beer A. J., Ruffani A., Haller B., et al. Eval- uation of Hybrid Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recur- rence After Radical Prostatectomy. J Nucl Med. 2015 May; 56 (5): 668–674. DOI: http://dx.doi.org/10.2967/jnumed.115.154153; Osborne J. R., Akhtar N. H., Vallabhajosula S., Anand A., Deh K., Tagawa S. T. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013 Feb; 31 (2): 144–154. DOI: http://dx.doi.org/10.1016/j.urolonc.2012.04.016; Rigatti P., Suardi N., Briganti A., Da Pozzo L. F., Tutolo M., Villa L., et al. Pelvic/ret- roperitoneal salvage lymph node dissection for patients treated with radical prostatec- tomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomog-raphy. Eur Urol. 2011; 60 (5): 935–943. DOI: http://dx.doi.org/10.1016/j.eururo.2011.07.060; Jilg C. A., Rischke H. C., Reske S. N., Henne K., Grosu A. L., Weber W., et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol. 2012; 188 (6): 2190–2197. DOI: http://dx.doi.org/10.1016/j. juro.2012.08.041; Tilki D., Mandel P., Seeliger F., Kretschmer A., Karl A., Ergün S., et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical pros- tatectomy. J Urol. 2015 Feb; 193 (2): 484–490. DOI: http://dx.doi.org/10.1016/j.juro.2014.08.096; Winter A., Henke R. P., Wawroschek F. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete bio- chemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up. BMC Urol. 2015 Feb 21; 15: 10. DOI: http://dx-.doi.org/10.1186/s12894–015–0004-y; Suardi N., Karnes J., Joniau S., et al. Salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and imaging-detected nodal metastases. J Urol. 2013; 189: e317–318.; Suardi N., Gandaglia G., Gallina A., Di Trapani E., Scattoni V., Vizziello D., et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow up of 5 years. Eur Urol. 2015 Feb; 67 (2): 299–309. DOI: http://dx.doi.org/10.1016/j.eururo.2014.02.011; https://www.rpmj.ru/rpmj/article/view/158
-
2Academic Journal
Authors: B. Ya. Alekseev, K. M. Nyushko, S. A. Reva, A. K. Nosov, D. G. Prokhorov, T. T. Andabekov, A. A. Krasheninnikov, E. Yu. Safronova, M. I. Shkol’nik, S. B. Petrov, A. S. Kalpinskiy, A. D. Kaprin, Б. Я. Алексеев, К. М. Нюшко, С. А. Рева, А. К. Носов, Д. Г. Прохоров, Т. Т. Андабеков, А. А. Крашенинников, Е. Ю. Сафронова, М. И. Школьник, С. Б. Петров, А. С. Калпинский, А. Д. Каприн
Source: Cancer Urology; Том 12, № 4 (2016); 70-80 ; Онкоурология; Том 12, № 4 (2016); 70-80 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-4
Subject Terms: многоцентровое исследование, oligometastases, lymphogenic progression, salvage lymphadenectomy, short-term treatment results, long-term treatment results, multicenter study, олигометастаз, лимфогенное прогрессирование, спасительная сальважная лимфаденэктомия, непосредственный результат лечения, отдаленный результат лечения
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/594/607; https://oncourology.abvpress.ru/oncur/article/view/594/617; Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России, 2016. 250 с. [Malignant tumors in Russia in 2014 (morbidity and fatality). Eds. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow: FGBU “Moskovskiy nauchno-issledovatel’skiy onkologicheskiy institute im. P.A. Gertsena” – filial FGBU “Natsional’nyy meditsinskiy issledovatel’skiy radiologicheskiy tsentr” Minzdrava Rossii, 2016. 250 p. (In Russ.)].; Han M., Partin A.W., Pound C.R. et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the15-year Johns Hopkins experience. Urol Clin North Am 2001;28(3):555–65. PMID: 11590814.; Simmons M.N., Stephenson A.J., Klein E.A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007;51(5):1175–84. DOI:10.1016/j.eururo.2007.01.015. PMID: 17240528.; Suardi N., Porter C.R., Reuther A.M. et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008;112(6):1254–63. DOI:10.1002/cncr.23293. PMID: 18286530.; Roehl K.A., Han M., Ramos C.G. et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172(3):910–4. DOI:10.1097/01.ju.0000134888.22332.bb. PMID: 15310996.; Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591–7. PMID: 10235151.; Schweizer M.T., Zhou X.C., Wang H. et al. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 2013;24(11):2881–6. DOI:10.1093/annonc/mdt335. PMID: 23946329.; Garcia J.R., Morenco C., Valls F. et al. Diagnostic performance of bone scintigraphy and 11C-choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. Rev Esp Med Nucl Imagen Mol 2015;34(3):155–61. DOI:10.1016/j.remn.2014.08.001. PMID: 25443648.; von Eyben F.E., Kairemo K. Metaanalysis of 11C-holine and 18F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 2014;35(3):221–30. DOI:10.1097/MNM.0000000000000040. PMID: 24240194.; Afshar-Oromieh A., Zechmann C.M., Malcher A. et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18Fcholine- based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41(1):11–20. DOI:10.1007/s00259-013-2525-5. PMID: 24072344.; Власова О.П., Герман К.Э., Крылов В.В. и др. Новые радиофармпрепараты для диагностики и лечения метастатического рака предстательной железы на основе ингибиторов простатспецифического мембранного антигена. Вестник Российской академии медицинских наук 2015;70(3):360–6. [Vlasova O.P., German K.E., Krylov V.V. et al. New radiopharmaceuticals based on inhibitors of prostate-specific membrane antigen for metastatic prostate cancer diagnostics and treatment. Vestnik Rossiyskoy akademii meditsinskikh nauk = Bulletin of the Russian Academy of Medical Sciences 2015;70(3):360–6. (In Russ.)]. DOI:10.15690/vramn.v70i3.1334.; Eiber M., Maurer T., Souvatzoglou M. et al. Evaluation of hybrid 68Ga-PSMA ligand PET/ CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015;56(5):668–74. DOI:10.2967/jnumed.115.154153. PMID: 25791990.; Osborne J.R., Akhtar N.H., Vallabhajosula S. at al. Prostate-specific membrane antigen-based imaging. Urol Oncol 2013;31(2):144–54. DOI:10.1016/j.urolonc.2012.04.016. PMID: 22658884.; Rigatti P., Suardi N., Briganti A. et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by 11C-choline positron emission tomography/computed tomography. Eur Urol 2011;60(5):935–43. DOI:10.1016/j.eururo.2011.07.060. PMID: 21840116.; Jilg C.A., Rischke H.C., Reske S.N. et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012;188(6):2190–7. DOI:10.1016/j.juro.2012.08.041. PMID: 23083862.; Tilki D., Mandel P., Seeliger F. et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. J Urol 2015;193(2):484–90. DOI:10.1016/j.juro.2014.08.096. PMID: 25180792.; Winter A., Henke R.P., Wawroschek F. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up. BMC Urol 2015;15:10. DOI:10.1186/s12894-015-0004-y. PMID: 25881245.; Suardi N., Karnes J., Joniau S. et al. Salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and imaging-detected nodal metastases. J Urol 2013;189:e317–8.; Suardi N., Gandaglia G., Gallina A. et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow up of 5 years. Eur Urol 2015;67(2):299–309. DOI:10.1016/j.eururo.2014.02.011. PMID: 24571959.; https://oncourology.abvpress.ru/oncur/article/view/594